Results 101 to 110 of about 170,525 (342)

Hepatic Steatosis and Steatohepatitis Is the Inevitability of Mixed Genesis

Gastroenterologìa, 2014
The analysis of the etiological and pathogenetic mechanisms of formation steatosis and steatohepatitis of mixed genesis is presented. It is shown that alcohol remains one of the main etiopathogenetic factors in the development of the hepatic steatosis ...
Yu.M. Stepanov
doaj   +1 more source

Toll-like receptor-mediated signaling cascade as a regulator of the inflammation network during alcoholic liver disease [PDF]

, 2014
Chronic abuse of alcohol leads to various histological abnormalities in the liver. These are conditions collectively known as alcoholic liver disease (ALD). Currently, ALD is considered to be one of the major causes of death worldwide.
Alisi, A., Ceccarelli, S, Nobili, V
core   +1 more source

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

Hepatology, 2018
The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of CC chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF).
S. Friedman, V. Ratziu, S. Harrison, M. Abdelmalek, G. Aithal, J. Caballería, S. Francque, G. Farrell, K. Kowdley, A. Craxì, K. Simon, L. Fischer, Liza Melchor-Khan, Jeffrey D. Vest, B. Wiens, P. Vig, S. Seyedkazemi, Z. Goodman, V. Wong, R. Loomba, F. Tacke, A. Sanyal, E. Lefebvre   +22 more
semanticscholar   +1 more source

Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments

Frontiers in Pharmacology, 2020
Non-alcoholic steatohepatitis (NASH) develops from non-alcoholic fatty liver disease (NAFLD). Currently, around 25% of the population is estimated to have NAFLD, and 25% of NAFLD patients are estimated to have NASH.
C. Peng, A. Stewart, O. Woodman, R. Ritchie, C. Qin   +4 more
semanticscholar   +1 more source

Homocysteine Exacerbates Pulmonary Fibrosis via Orchestrating Syntaxin 17 Homocysteinylation of Alveolar Type II Cells

Advanced Science, EarlyView.
The study identifies elevated homocysteine (Hcy) levels in idiopathic pulmonary fibrosis patients' samples, with alveolar type 2 cells as the primary site of Hcy metabolism. Methionine synthase reductase downregulation in these cells exacerbates fibrosis, while folate administration reduces Hcy levels and alleviates fibrosis.
Jiefeng Huang, Ke Fang, Wuyan Lu, Rongrong Wu, Yuanyuan Chen, Linxiao Li, Zihao Hu, Zixin Cai, Yu Jiang, Xinli Fan, Jinyi Deng, Guangpeng Liu, Zhuang Luo, Lei Cui, Shuaijun Li   +14 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source

Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis [PDF]

, 2019
BACKGROUND: The last decade has seen a rapid growth in the number of clinical trials enrolling patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH).
Adams, Aithal, Andrade, Angulo, Armstrong, Arroyo, Athyros, Avigan, Banderas, Bays, Belfort, Bjornsson, Caldwell, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Cusi, De Denus, De Santis, Dutta, Eijgenraam, Ekstedt, Ekstedt, European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), Fontana, Friedman, Friedman, Giannini, Guha, Hayashi, Hoofnagle, Hyysalo, Im, Jalan, Kaplan, Kleiner, Kleiner, Kolwankar, Kowdley, Kullak-Ublick, Kwok, LaBrecque, Lavine, Lewis, Lewis, Liddle, Lo Re, Loomba, Maurice, McPherson, Moylan, Mudaliar, Neuschwander-Tetri, Panteghini, Pantsari, Patel, Patel, Pfeffer, Ratziu, Ratziu, Regev, Reid, Robles-Diaz, Rockstroh, Russo, Sanyal, Sanyal, Sanyal, Scorletti, Senior, Siddiqui, Stefan, Tarantino, Temple, Valenti, Verna, Vilar-Gomez, Vuppalanchi, Vuppalanchi, Vuppalanchi, Watkins, Weltman, Wong, Younossi, Younossi, Zelber-Sagi, Zhou, Zimmerman   +91 more
core   +1 more source

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

Hepatology, 2020
Cenicriviroc (CVC) is a C‐C chemokine receptors type 2 and 5 dual antagonist under evaluation for treating liver fibrosis in adults with nonalcoholic steatohepatitis (NASH).
V. Ratziu, A. Sanyal, S. Harrison, V. Wong, S. Francque, Z. Goodman, G. Aithal, K. Kowdley, S. Seyedkazemi, L. Fischer, R. Loomba, M. Abdelmalek, F. Tacke   +12 more
semanticscholar   +1 more source

Inhibition of Tumor Lipogenesis and Growth by Peptide‐Based Targeting of SREBP Activation

Advanced Science, EarlyView.
A peptide that replicates the amino acid sequence in Insig1/2 loop 1 inhibits the IGF1‐induced interaction between PCK1 and Insig1/2, PCK1‐mediated phosphorylation of Insig1/2, and SREBP activity‐dependent lipid synthesis. Administration of the LNP‐Insig1/2 loop 1 peptide effectively attenuates tumor growth and sensitizes tumors to the antitumor effect
Shudi Luo, Huang Yang, Xiaoming Jiang, Zheng Wang, Xuxiao He, Ying Meng, Shan Li, Min Li, Daqian Xu, Zhengwei Mao, Zhimin Lu   +10 more
wiley   +1 more source

CD11b+CD43hiLy6Clo splenocyte‐derived macrophages exacerbate liver fibrosis via spleen–liver axis

Hepatology, EarlyView., 2022
A population of splenic monocytes migrate into the liver and shift to macrophages, which account for the exacerbation of liver fibrosis. Abstract Background and Aims Monocyte‐derived macrophages (MoMFs), a dominant population of hepatic macrophages under inflammation, play a crucial role in liver fibrosis progression.
Shaoying Zhang, Dan Wan, Mengchen Zhu, Guihu Wang, Xurui Zhang, Na Huang, Jian Zhang, Chongyu Zhang, Qi Shang, Chen Zhang, Xi Liu, Fanfan Liang, Chunyan Zhang, Guangyao Kong, Jing Geng, Libo Yao, Shemin Lu, Yongyan Chen, Zongfang Li   +18 more
wiley   +1 more source